CY1105080T1 - Ενωσεις θειενοπυρρολυλιου και φουρανοπυρρολυλιου και η χρηση τους ως συνδετες η4 υποδοχεα ισταμινης - Google Patents
Ενωσεις θειενοπυρρολυλιου και φουρανοπυρρολυλιου και η χρηση τους ως συνδετες η4 υποδοχεα ισταμινηςInfo
- Publication number
- CY1105080T1 CY1105080T1 CY20061100955T CY061100955T CY1105080T1 CY 1105080 T1 CY1105080 T1 CY 1105080T1 CY 20061100955 T CY20061100955 T CY 20061100955T CY 061100955 T CY061100955 T CY 061100955T CY 1105080 T1 CY1105080 T1 CY 1105080T1
- Authority
- CY
- Cyprus
- Prior art keywords
- furanopyrrolyl
- thienopyrrolyl
- compounds
- histamine receptor
- receptor binders
- Prior art date
Links
- -1 FURANOPYRROLYL COMPOUNDS Chemical class 0.000 title abstract 2
- 102000000543 Histamine Receptors Human genes 0.000 title 1
- 108010002059 Histamine Receptors Proteins 0.000 title 1
- 239000011230 binding agent Substances 0.000 title 1
- 102000004187 Histamine H4 receptors Human genes 0.000 abstract 1
- 108090000796 Histamine H4 receptors Proteins 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40872302P | 2002-09-06 | 2002-09-06 | |
| PCT/US2003/028017 WO2004022537A2 (en) | 2002-09-06 | 2003-09-05 | Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1105080T1 true CY1105080T1 (el) | 2009-11-04 |
Family
ID=31978666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061100955T CY1105080T1 (el) | 2002-09-06 | 2006-07-07 | Ενωσεις θειενοπυρρολυλιου και φουρανοπυρρολυλιου και η χρηση τους ως συνδετες η4 υποδοχεα ισταμινης |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7226938B2 (enExample) |
| EP (1) | EP1543011B1 (enExample) |
| JP (1) | JP4596915B2 (enExample) |
| AT (1) | ATE325125T1 (enExample) |
| AU (1) | AU2003272285A1 (enExample) |
| CA (1) | CA2497868C (enExample) |
| CY (1) | CY1105080T1 (enExample) |
| DE (1) | DE60305052T2 (enExample) |
| DK (1) | DK1543011T3 (enExample) |
| ES (1) | ES2264534T3 (enExample) |
| PT (1) | PT1543011E (enExample) |
| WO (1) | WO2004022537A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003272285A1 (en) * | 2002-09-06 | 2004-03-29 | Janssen Pharmaceutica, N.V. | Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands |
| GB0222912D0 (en) * | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0222909D0 (en) * | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| WO2005031308A2 (en) * | 2003-09-26 | 2005-04-07 | Janssen Pharmaceutica N.V. | Analyzing histamine h4 receptor-mediated effects in whole blood |
| NZ548212A (en) * | 2003-12-29 | 2010-07-30 | Sepracor Inc | Pyrrole and pyrazole DAAO inhibitors |
| BRPI0512252A (pt) | 2004-06-18 | 2008-02-19 | Biolipox Ab | composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto |
| EP1812113A1 (en) * | 2004-11-11 | 2007-08-01 | Argenta Discovery Limited | Pyrimidine compounds as histamine modulators |
| EP1776982A1 (en) * | 2005-10-18 | 2007-04-25 | Argenta Discovery Limited | Pyrimidine compounds as histamine modulators |
| EP1671972A1 (en) * | 2004-11-24 | 2006-06-21 | Pfizer Limited | Octahydropyrrolo[3,4-c]pyrrole derivatives |
| EP1846409A1 (en) * | 2004-11-24 | 2007-10-24 | Pfizer Limited | Octahydropyrrolo[3,4-c]pyrrole derivatives |
| WO2006077366A1 (en) | 2005-01-19 | 2006-07-27 | Biolipox Ab | Indoles useful in the treatment of inflammation |
| WO2007006003A2 (en) | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| EP1767537A1 (en) * | 2005-09-21 | 2007-03-28 | Cellzome (UK) Ltd. | Pyrimidine compounds for the treatment of inflammatory disorders |
| NL2000323C2 (nl) * | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
| KR101294014B1 (ko) | 2006-01-06 | 2013-08-09 | 선오비온 파마슈티컬스 인코포레이티드 | 모노아민 재흡수 저해제로서의 시클로알킬아민 |
| US8053603B2 (en) | 2006-01-06 | 2011-11-08 | Sunovion Pharmaceuticals Inc. | Tetralone-based monoamine reuptake inhibitors |
| ATE478067T1 (de) | 2006-03-31 | 2010-09-15 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors |
| DK2816024T3 (en) | 2006-03-31 | 2017-10-30 | Sunovion Pharmaceuticals Inc | CHIRALE AMINER |
| WO2007120690A2 (en) * | 2006-04-10 | 2007-10-25 | Janssen Pharmaceutica N.V. | Combination histamine h1r and h4r antagonist therapy for treating pruritus |
| US20080058395A1 (en) * | 2006-06-30 | 2008-03-06 | Sepracor Inc. | Fused heterocyclic inhibitors of D-amino acid oxidase |
| KR20090024823A (ko) * | 2006-06-30 | 2009-03-09 | 세프라코 아이엔시. | D-아미노산 옥시다제의 융합된 헤테로사이클 억제제 |
| US7579370B2 (en) | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US20080082066A1 (en) * | 2006-10-02 | 2008-04-03 | Weyerhaeuser Co. | Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks |
| US7985745B2 (en) | 2006-10-02 | 2011-07-26 | Abbott Laboratories | Method for pain treatment |
| EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| WO2008074445A1 (en) * | 2006-12-18 | 2008-06-26 | Ucb Pharma, S.A. | Novel tricyclic and heterotricyclic derivatives, processes for preparing them, pharmaceutical compositions thereof |
| US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| US20090099248A1 (en) * | 2007-01-18 | 2009-04-16 | Sepracor Inc. | Inhibitors of d-amino acid oxidase |
| MX2009012685A (es) | 2007-05-31 | 2009-12-14 | Sepracor Inc | Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina. |
| UA100567C2 (ru) * | 2008-06-12 | 2013-01-10 | Янссен Фармацевтика Нв | Использование антагонистов н4-гистаминовых рецепторов для лечения послеоперационных спаек |
| US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
| WO2010017418A1 (en) * | 2008-08-07 | 2010-02-11 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| EP2201982A1 (en) | 2008-12-24 | 2010-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Histamine H4 receptor antagonists for the treatment of vestibular disorders |
| US20120277238A1 (en) * | 2009-07-31 | 2012-11-01 | Shionogi & Co., Ltd | Pharmaceutical composition containing fused hetero-ring derivative |
| WO2011017634A2 (en) * | 2009-08-07 | 2011-02-10 | Sepracore Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| HUE039713T2 (hu) | 2012-06-08 | 2019-02-28 | Sensorion | H4 receptor inhibitorok tinnitus kezelésére |
| JO3516B1 (ar) | 2013-03-06 | 2020-07-05 | Janssen Pharmaceutica Nv | مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4 |
| TW201729810A (zh) | 2015-10-26 | 2017-09-01 | 札爾科製藥公司 | 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法 |
| CN109499595B (zh) * | 2018-11-16 | 2021-10-08 | 中国林业科学研究院林产化学工业研究所 | 一种氧还原反应(orr)催化剂gpncs及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2571723B1 (fr) * | 1984-10-12 | 1988-08-26 | Lipha | Derives de thieno et furo-(2,3-c) pyrroles, procedes de preparation et medicaments les contenant |
| NZ223654A (en) * | 1987-03-09 | 1990-03-27 | Janssen Pharmaceutica Nv | 1-alkyl-substituted-benzimidazole-4-piperidinamines and pharmaceutical compositions |
| GB9803228D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| PT1088824E (pt) | 1999-09-30 | 2004-04-30 | Pfizer Prod Inc | Pirrolil-amidas biciclicas como inibidores de glicogenio-fosforilase |
| EP1136071A3 (en) | 2000-03-22 | 2003-03-26 | Pfizer Products Inc. | Use of glycogen phosphorylase inhibitors |
| WO2002072548A2 (en) * | 2001-03-09 | 2002-09-19 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic compounds and their use as histamine h4 ligands. |
| AU2003272285A1 (en) * | 2002-09-06 | 2004-03-29 | Janssen Pharmaceutica, N.V. | Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands |
-
2003
- 2003-09-05 AU AU2003272285A patent/AU2003272285A1/en not_active Abandoned
- 2003-09-05 ES ES03754461T patent/ES2264534T3/es not_active Expired - Lifetime
- 2003-09-05 JP JP2004534722A patent/JP4596915B2/ja not_active Expired - Fee Related
- 2003-09-05 DK DK03754461T patent/DK1543011T3/da active
- 2003-09-05 US US10/656,059 patent/US7226938B2/en not_active Expired - Lifetime
- 2003-09-05 PT PT03754461T patent/PT1543011E/pt unknown
- 2003-09-05 DE DE60305052T patent/DE60305052T2/de not_active Expired - Lifetime
- 2003-09-05 WO PCT/US2003/028017 patent/WO2004022537A2/en not_active Ceased
- 2003-09-05 AT AT03754461T patent/ATE325125T1/de active
- 2003-09-05 EP EP03754461A patent/EP1543011B1/en not_active Expired - Lifetime
- 2003-09-05 CA CA2497868A patent/CA2497868C/en not_active Expired - Fee Related
-
2006
- 2006-07-07 CY CY20061100955T patent/CY1105080T1/el unknown
-
2007
- 2007-04-13 US US11/735,311 patent/US20070185131A1/en not_active Abandoned
- 2007-04-13 US US11/735,306 patent/US7645758B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004022537A3 (en) | 2004-05-06 |
| US20070185131A1 (en) | 2007-08-09 |
| ES2264534T3 (es) | 2007-01-01 |
| US20040048878A1 (en) | 2004-03-11 |
| DE60305052D1 (de) | 2006-06-08 |
| EP1543011B1 (en) | 2006-05-03 |
| US7226938B2 (en) | 2007-06-05 |
| AU2003272285A1 (en) | 2004-03-29 |
| DE60305052T2 (de) | 2006-12-21 |
| US20070185120A1 (en) | 2007-08-09 |
| AU2003272285A8 (en) | 2004-03-29 |
| PT1543011E (pt) | 2006-08-31 |
| ATE325125T1 (de) | 2006-06-15 |
| DK1543011T3 (da) | 2006-08-07 |
| CA2497868C (en) | 2010-11-30 |
| JP4596915B2 (ja) | 2010-12-15 |
| US7645758B2 (en) | 2010-01-12 |
| JP2006500394A (ja) | 2006-01-05 |
| CA2497868A1 (en) | 2004-03-18 |
| WO2004022537A2 (en) | 2004-03-18 |
| EP1543011A2 (en) | 2005-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1543011E (pt) | Composto de tienopirrolilo e furanopirrolilo e sua utilizacao como ligandos do receptor h4 da histamina | |
| NO20052591L (no) | Pyridopyrolizin og pyridoindolizinderivater | |
| CY1110965T1 (el) | Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου | |
| DE60215000D1 (de) | DIHYDROPYRROLOi1,2-AöINDOL- UND TETRAHYDROPYRIDOi1,2-AöINDOLDERIVATE ALS PROSTAGLANDIN REZEPTOR ANTAGONISTEN | |
| CY1110954T1 (el) | Ημιστερεες βλεννοκολλωδεις φαρμακοτεχνικες μορφες | |
| ATE508114T1 (de) | Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung | |
| CY1106476T1 (el) | Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες | |
| ATE365165T1 (de) | Diaminopyrimidine und deren verwendung als angiogenesehemmer | |
| CY1109741T1 (el) | Sns-595 και μεθοδοι χρησης αυτου | |
| CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
| DE50310516D1 (de) | Fredericamycin-derivate | |
| ATE448232T1 (de) | Substituierte heterozyklen | |
| NO20064547L (no) | Fremgangsmater for behandling av HIV infeksjon | |
| ECSP077277A (es) | Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas | |
| UY28098A1 (es) | Derivados de anilinopirazol útiles en el tratamiento de la diabetes | |
| CY1106409T1 (el) | Παραγωγα κινολινης | |
| DE602004017326D1 (de) | Tetrahydrocarbazolderivate und deren pharmazeutische verwendung | |
| NO20054371L (no) | Somatostatin-dopamin kimaere analoger | |
| SE0302304D0 (sv) | Novel compounds | |
| ATE413392T1 (de) | Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren | |
| BR0313611A (pt) | Uso da combinação de ciclesonida e anti-histaminas para o tratamento de rinite alérgica | |
| CY1108809T1 (el) | Μεθοδοι κατασκευης 6-[(4.5-διϋδρο-1η-ιμιδαζολ-2-υλ)αμινο-]-7-μεθυλ-1η-βενζιμιδαζολο-4-kapboniτριλιου και προτιμωμενη μορφη αλατος αυτου | |
| ATE417856T1 (de) | Motilidverbindungen | |
| NO20055563L (no) | Midler for behandlingen av lavere abdominale lidelser | |
| DE60305053D1 (de) | Pyrimidinderivate als selektive cox-2-inhibitoren |